Silence is
Healthy When

mouse scroll

a face lift for the soft palate

An estimated 1 in 4 adults suffers from a clinically-harmful level of snoring. In many cases, soft palate tissue is the source of the airway obstruction. Zelegent has developed a technology that allows physicians to quickly and safely alleviate some cases of snoring through an office-based treatment. Simply put, the procedure works like "a face lift for the soft palate"™.

how it works
+

introducing Elevoplasty™

A minimally-invasive procedure that lifts soft palate tissue to
reduce or eliminate snoring.*

learn more
*Investigational device, results currently being generated in multi-center U.S. pivotal clinical trial.

Minimally
Invasive
Procedure

+

The minimally-invasive procedure is performed in-office under local anesthetic and involves no downtime.

Completed in
Approximately
10 Minutes

+

Treatment for a vexing healthcare challenge can be completed in an approximate ten-minute office procedure.

An
Anatomic
Remedy

+

The soft palate is lifted to anatomically fix a root cause of snoring without the need to wear a treatment device during sleep.

Silence is Healthy

Learn more about the S.I.LE.N.C.E. clinical study, a multi-center clinical trial to evaluate the safety and efficacy of Elevoplasty™.

learn more

latest news

Jun 21, 2018

Zelegent, Inc. Elevoplasty™ Procedure Receives U.S. Patent

First issued patent of a portfolio of applications covering the new minimally-invasive procedure to treat snoring. IRVINE, CA –June 21st, 2018 – Zelegent, Inc., a medical technology company ...
Mar 13, 2017

Zelegent, Inc. Launches Multi-Center Snoring Reduction Trial

Zelegent, Inc., a clinical-stage medical technology company developing innovative tools for otolaryngologist sleep specialists, today announced the beginning of enrollment in its multi-center pivotal snoring reduction trial, the S.I.LE.N.C.E. study.
Jun 08, 2015

Zelegent, Inc. Pilot Study Results Show Significant Improvement in All Study Endpoints

Zelegent, Inc. presented clinical outcomes from its pilot clinical study today at the 3rd Congress of European Otorhinolaryngology and Head and Neck Surgery (ORL-HNS) in Prague, Czech Republic.